ReviewPLoS neglected tropical diseases2025
Mpox in Africa: What we know and what is still lacking.
Review in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Mpox knowledge and perception in Africa: a systematic review and meta-analysis.BMC public health · 2026Pooled it
- Mpox vaccine acceptance and uptake in Africa: a systematic review and meta-analysis.BMC global and public health · 2026Pooled it
- Mpox in Africa: one year continental response outcomes and way forward.BMJ global health · 2026Article
- Clinical trial laboratory principles for emerging infectious disease research in resource-limited settings.Trends open · 2026Article
- Decentralizing testing capacity of mpox in Africa: a narrative review.The Lancet regional health. Africa · 2026Review
- In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Beyond counting the numbers - focused outbreaks response strategies are needed to control the mpox outbreak in Africa.One health outlook · 2026Article
- Syndemic convergence of mpox and HIV crisis in the Philippines: implications for integrated and responsive public health action.International journal for equity in health · 2026Article
- Rapid Qualitative Approaches in Pandemic Research: Protocol for an Exploratory Qualitative Multimethod Study (VERDIQual) on Mpox in Italy, Nigeria, Thailand, and the United Kingdom.JMIR research protocols · 2026Article
- Advancing epidemic intelligence: evaluating Senegal's mpox surveillance system and readiness for AI-driven predictive modelling.Frontiers in public health · 2026Article
- Weaknesses and strengths in the emergency response and management of the first mpox case in The Gambia.Journal of public health in Africa · 2026Article
- Determinants of knowledge and attitudes toward Mpox among medical students: A cross-sectional study from Kurdistan region of Iraq.PloS one · 2026Article
- Article
- The emergence of Mpox in Ethiopia: implications for public health action.Tropical diseases, travel medicine and vaccines · 2025Article
- Pox-AbDab: the orthopoxvirus antibody database.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging as a major global health threat, Mpox previously known as Monkeypox has drawn attention due to a worrying surge in cases. This zoonotic disease, native to Central and West Africa, is marked by fever, rash, and lymphadenopathy and is primarily spread through direct contact with infected animals or people and indirectly through contaminated objects. Recent studies have indicated possible sexual transmission, underscoring how human behavior and environmental changes are increasing its prevalence, even though human-to-human transmission is less efficient than that of smallpox. Mpox is endemic in several African countries, and currently, the infection has spread in non-endemic countries, including Rwanda, Uganda, and Kenya. Democratic Republic of Congo is the epicenter of the current Mpox outbreak. From January 1, 2022, to August 6, 2024, sixteen African countries reported Mpox outbreak. Several factors, including population immunity deficiencies and changes to the environment and ecology, have led to the widespread of Mpox in Africa. Challenges such as the fragile healthcare system, limited vaccine availability and access, weak surveillance, and low public awareness poses difficulty in containing the infection in affected countries. Given the potential of Mpox to disrupt several sectors including health systems, which may ultimately reverse progress in achieving the sustainable development goals by 2030. It is imperative for countries, both within and outside Africa, to extend financial aid and human resources to combat the infection effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.